Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo antídoto inhibidor de trombina directo y seguro

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20140930004
Publicado:
12/01/2016
Caducidad:
26/04/2016
Resumen:
Una universidad alemana ofrece un nuevo antídoto inhibidor de trombina (DTI) directo y seguro capaz de antagonizar la función anticoagulante de varios DTI, por ejemplo, dabigatrán, hirudin, bivalirudin y argatrobán, y reducir considerablemente la concentración de DTI en el primer minuto después de la aplicación. Además no induce una respuesta procoagulante. Se buscan compañías farmacéuticas (productores de anticoagulantes) con el fin de continuar con el desarrollo, realizar ensayos clínicos, licenciar o vender los derechos de propiedad intelectual.

Details

Tittle:
Novel safe direct thrombin inhibitor antidote
Summary:
A German university provides a novel direct thrombin inhibitor (DTI) antidote. It is able to antagonize the anticoagulant function of various DTI, e.g. dabigatran, and reduces the DTI concentration significantly within the first minute after application. Furthermore it does not induce a procoagulant response. They look for pharmaceutical companies, e.g. producer of anticoagulants. The desired co-operations are further development, clinical trial studies, in-licensing or sale of IP-rights.
Description:
Direct acting thrombin inhibitor, such as dabigatran and argatroban are successfully used for the prevention and treatment of thromboembolic disorders. Even though clinical studies demonstrate an improved efficacy-to-safety index of dabigatran, as with all other anticoagulants bleeding is still a problem. In the absence of a specific antidote major bleeding complications including life-threatening haemorrhage and urgent surgical interventions are difficult to manage.

A German university provides a safe direct thrombin inhibitor (DTI-)antidote able to antagonize the anticoagulant functions of various DTI, such as dabigatran, hirudin, bivalirudin and argatroban.

The exosite structures of thrombin are blocked by complex formation between thrombin and a recently developed aptamer . As this aptamer does not block the active center of thrombin, the aptamer caged thrombin (Apta-thrombin) retains full reactivity towards DTI but looses its procoagulant functions. This is an important prerequisite to avoid unwanted thrombotic site effects of the DTI antidote.

The ability of apta-thrombin to antagonize the anticoagulant functions of various DTI has been demonstrated in plasma-based studies and in a mouse-model. A prothrombotic response was not induced by apta-thrombin as measured by molecular activation markers. This feature renders apta-thrombin a safe DTI antidote.

The university is looking for pharmaceutical companies, e.g. producer of anticoagulants. The desired co-operation is further development and clinical trial studies, in-licensing or sale of IP-rights.
Advantages and Innovations:
- Novel DTI-antidote is able to antagonize the anticoagulant
function of direct acting thrombin inhibitors:
-- dabigatran
-- argatroban
- Reduces the DTI-concentration significantly within the first minute after application
- Does not induce a procoagulant response
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
EP applied for

Partner sought

Type and Role of Partner Sought:
Pharmaceutical companies, e.g. producer of anticoagulants.
Kind of cooperation which is sought:
- further development and clinical trial studies
- in-licensing
- sale of IP-rights

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001011 Enfermedades circulatorias y del corazón
03004007 Pharmaceutics